| 1 |
Guillevin L, Pagnoux C, Seror R, et al; French Vasculitis Study Group (FVSG). The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort [J]. Medicine (Baltimore), 2011, 90(1): 19-27.
|
| 2 |
Nguyen Y, Puéchal X; French Vasculitis Study Group. Reply to the comment on: Microscopic polyangiitis: clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry by Nguyen et al [J]. Clin Exp Rheumatol, 2021, 39 Suppl, 128(1): 9-10.
|
| 3 |
Slot MC, Tervaert JW, Franssen CF, et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement [J]. Kidney Int, 2003, 63(2): 670-677.
|
| 4 |
Kronbichler A, Bajema IM, Bruchfeld A, et al. Diagnosis and management of ANCA-associated vasculitis [J]. Lancet, 2024, 403(10427): 683-698.
|
| 5 |
陈建, 牛艳慧, 李桂莲, 等. 抗中性粒细胞胞质抗体相关性血管炎190例临床特点分析 [J]. 中华医学杂志, 2009, 89(36): 2548-2551.
|
| 6 |
Gaber LW, Wall BM, Cooke CR. Coexistence of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis and membranous glomerulopathy [J]. Am J Clin Pathol, 1993, 99(2): 211-215.
|
| 7 |
Kojima T, Oda T. Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis [J]. Front Med (Lausanne), 2022, 9: 1031445.
|
| 8 |
Tominaga K, Toda E, Takeuchi K, et al. Myeloperoxidase-associated membranous nephropathy in antineutrophil cytoplasmic antibody-associated glomerulonephritis [J]. Kidney Int Rep, 2024, 9(7): 2240-2249.
|
| 9 |
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus [J]. Ann Rheum Dis, 2019, 78(9): 1151-1159.
|
| 10 |
Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) [J]. Ann Rheum Dis, 2009, 68(12): 1827-1832.
|
| 11 |
Park PG, Song JJ, Park YB, et al. Clinical application of low erythrocyte sedimentation rate/high C-reactive protein to antineutrophil cytoplasmic antibody-associated vasculitis [J]. J Clin Lab Anal, 2022, 36(2): e24237.
|
| 12 |
Yagiz Ozogul Y, Esatoglu SN, Ozogul M, et al. Central nervous system involvement and mimickers in ANCA associated vasculitis [J]. J Neurol, 2025, 272(8): 492.
|
| 13 |
Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials [J]. Blood, 2020, 136(9): 1091-1104.
|
| 14 |
Specks U, Merkel PA, Seo P, et al; RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis [J]. N Engl J Med, 2013, 369(5): 417-427.
|